New pill shows promise for Hard-to-Treat ovarian cancer
Disease control
Not yet recruiting
This study tests a new oral drug called DAT-2645 in up to 30 people with advanced or metastatic ovarian cancer that has a BRCA1/2 mutation or is HRD-positive. Participants take the drug daily in 21-day cycles. The main goal is to see if the drug shrinks tumors, and researchers wi…
Phase: PHASE2 • Sponsor: Danatlas Pharmaceuticals Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC